Rhythm Pharmaceuticals (RYTM) Short term Debt (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 4 years of Short term Debt data on file, last reported at $10.1 million in Q1 2026.

• On a quarterly basis, Short term Debt rose 537.11% year-over-year to $10.1 million in Q1 2026; TTM through Mar 2026 was $10.1 million, a 537.11% increase from a year earlier, with the FY2025 full-year figure at $7.3 million, up 373.46% from the prior year.
• Short term Debt for Q1 2026 stood at $10.1 million, up from $7.3 million in the prior quarter.
• Over the last five years, Short term Debt for RYTM reached as high as $10.1 million in Q1 2026 and fell as low as $1.5 million in Q4 2024.
• Historically, Short term Debt has averaged $5.0 million across 3 years, with a median of $4.7 million in 2025.
• Across the five-year window, Short term Debt jumped 373.46% in 2025 and jumped 537.11% in 2026, its largest moves.
• Year by year, Short term Debt stood at $1.5 million in 2024, then soared by 373.46% to $7.3 million in 2025, then surged by 38.84% to $10.1 million in 2026.
• Per Business Quant data, the three most recent Short term Debt figures were $10.1 million in Q1 2026, $7.3 million in Q4 2025, and $5.6 million in Q3 2025.